GlaxoSmithKline plc announced that once-daily Avamys™ (fluticasone furoate) nasal spray has received a positive opinion from the European Medicines Agency (EMEA) for the treatment of the symptoms of allergic rhinitis in adults, adolescents (12 years and over) and children (6-11 years).
Phase III studies show Avamys, a novel enhanced-affinity steroid, demonstrated superior efficacy to placebo in treating overall nasal allergy symptoms including congestion, sneezing, and itchy and runny nose in adults and children suffering from seasonal or year-round allergies.[1],[2],[3],[4] In addition, Avamys is the first intranasal corticosteroid spray to demonstrate consistently significant improvement in relieving overall eye symptoms associated with allergy such as red, itchy, burning and watery eyes in adult and adolescent patients with seasonal allergies.[5],1
“Today’s positive opinion for Avamys is important for the 60 million Europeans whose quality of life is seriously impacted by allergic rhinitis.” Said Andrew Witty, President of GSK Pharmaceuticals, Europeand CEO Designate. “Up to 70% of people with allergic rhinitis suffer from symptoms that affect both the nose and the eyes and Avamys is the only prescription nasal steroid spray that has demonstrated consistent efficacy within clinical studies, in relieving both these symptoms associated with an allergic response. Importantly this relief from the main symptoms of allergic rhinitis has been shown to be sustained for over 24 hours.”
— Article compiled by Dr. Anil Singhal, MD(Hom.) from medical news release.